rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Silo Pharma, Inc.

SILO · Nasdaq

Health CareBiotechnologyNot moving yet

SILO stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 75.6% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$7,660
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
7 (-7)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$5,384Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months0
Buyers · sellers1 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders7-7 on the quarter
New · exited1 · 8
Reported value$655K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
AdvisorShares Investments LLCreduced · filed 11 Aug 202675,582$469K-588,383−88.6%
CITADEL ADVISORS LLCreduced · filed 14 Aug 202616,800$104K-4,648−21.7%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202611,956$74K+735+6.6%
VANGUARD FIDUCIARY TRUST COreduced · filed 13 Aug 2026874$5,428-12,226−93.3%
Tower Research Capital LLC (TRC)reduced · filed 11 Aug 2026181$1,124-1,496−89.2%
HARBOUR INVESTMENTS, INC.new · filed 12 Aug 202614$87+14
31 Mar 2023 – 30 Jun 2026
51014Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Eric Weisblum Company insiderChief Executive Officer · last 15 Dec 202542 · 0
Daniel E. Ryweck Company insiderChief Financial Officer · last 23 May 20251 · 0
Jeff Pavell Company insiderDirector · last 23 May 20250 · 0
Kevin Munoz Company insiderDirector · last 23 May 20250 · 0
Wayne Linsley Company insiderDirector · last 23 May 20250 · 0
Van Eps Parker Company insiderDirector · last 10 Feb 20160 · 0
Leonard M. Schiller Company insiderDirector · last 1 Jan 20150 · 0
Joel Alan Stone Company insiderDirector · last 1 Jan 20150 · 0
Richard Brand Company insiderChairman and CEO · last 20 Jun 20130 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202538.6%
Return on capital employedFY 2025 · to 31 Dec 2025-61.5%
Share count trendFY 2025 · to 27 Mar 20266.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$4.7M

Analyst forecasts

No analyst forecasts yet.